Remy Kenneth E, Hall Mark W, Cholette Jill, Juffermans Nicole P, Nicol Kathleen, Doctor Allan, Blumberg Neil, Spinella Philip C, Norris Philip J, Dahmer Mary K, Muszynski Jennifer A
Department of Pediatrics, Division of Pediatric Critical Care, Washington University School of Medicine, St Louis, Missouri.
Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio.
Transfusion. 2018 Mar;58(3):804-815. doi: 10.1111/trf.14488. Epub 2018 Jan 30.
Red blood cell (RBC) transfusion is common in critically ill, postsurgical, and posttrauma patients in whom both systemic inflammation and immune suppression are associated with adverse outcomes. RBC products contain a multitude of immunomodulatory mediators that interact with and alter immune cell function. These interactions can lead to both proinflammatory and immunosuppressive effects. Defining clinical outcomes related to immunomodulatory effects of RBCs in transfused patients remains a challenge, likely due to complex interactions between individual blood product characteristics and patient-specific risk factors. Unpacking these complexities requires an in-depth understanding of the mechanisms of immunomodulatory effects of RBC products. In this review, we outline and classify potential mediators of RBC transfusion-related immunomodulation and provide suggestions for future research directions.
红细胞(RBC)输血在重症、术后及创伤后患者中很常见,在这些患者中,全身炎症和免疫抑制均与不良预后相关。红细胞制品含有多种免疫调节介质,这些介质可与免疫细胞功能相互作用并改变其功能。这些相互作用可导致促炎和免疫抑制作用。确定与输注患者中红细胞免疫调节作用相关的临床结局仍然是一项挑战,这可能是由于个体血液制品特征与患者特异性风险因素之间存在复杂的相互作用。剖析这些复杂性需要深入了解红细胞制品免疫调节作用的机制。在本综述中,我们概述并分类了与红细胞输血相关免疫调节的潜在介质,并为未来的研究方向提供了建议。